What this study is
This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how this changes brain responses or food preferences.
What's being tested
- Exercise
Intervention · BEHAVIORAL
- Diet
Intervention · BEHAVIORAL
Study details
- Sponsor
- University of Colorado, Denver
- Conditions
- Schizophrenia
- Enrolling
- 140 people
- Starts
- 2014-08
- Est. completion
- 2025-09
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years – 70 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Diagnosis of schizophrenia or schizoaffective disorder
- Between 21 and 70 years of age
- Currently prescribed either olanzapine, risperidone, clozapine, or haloperidol, OR not currently being treated with any neuroleptic medications
- Weight stable within 5 percent for the last 6 months
You can't join if
- Pregnancy
- Substance abuse
- Significant endocrine/metabolic disease (e.g., uncontrolled hypertension, severe hypertriglyceridemia)
- MRI-specific exclusion criteria (e.g., claustrophobia, metal in the body)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
- Kristina T Legget, PhD · Contact303-724-5809kristina.legget@ucdenver.edu
Recruiting
Study team
Sponsor
University of Colorado, Denver
Study ID 14-1282
Principal investigator
Jason Tregellas, Ph.D.
University of Colorado, Denver
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.